<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5560676</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0183453</article-id><article-id pub-id-type="publisher-id">PONE-D-17-14006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Ruminants</subject><subj-group><subject>Sheep</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>DNA construction</subject><subj-group><subject>Plasmid Construction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>DNA construction</subject><subj-group><subject>Plasmid Construction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>B Vitamins</subject><subj-group><subject>Thiamine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>B Vitamins</subject><subj-group><subject>Thiamine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic Acids</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject><subj-group><subject>Food</subject><subj-group><subject>Chocolate</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject><subj-group><subject>Food</subject><subj-group><subject>Chocolate</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Library Screening</subject><subj-group><subject>Recombination-Based Assay</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Library Screening</subject><subj-group><subject>Recombination-Based Assay</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Analysis of multidrug resistant group B streptococci with reduced penicillin susceptibility forming small, less hemolytic colonies </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Group B streptococci with reduced penicillin susceptibility forming small, less hemolytic colonies</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Banno</surname><given-names>Hirotsugu</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3783-6333</contrib-id><name><surname>Kimura</surname><given-names>Kouji</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Yosuke</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sekizuka</surname><given-names>Tsuyoshi</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuroda</surname><given-names>Makoto</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Wanchun</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wachino</surname><given-names>Jun-ichi</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Keiko</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shibayama</surname><given-names>Keigo</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arakawa</surname><given-names>Yoshichika</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Bacteriology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Microbiology Laboratory, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Asahi-ku, Yokohama, Kanagawa, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Pathogen Genomic Center, National Institute of Infectious Diseases, Shinjyuku-ku, Tokyo, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Bacteriology II, National Institute of Infectious Diseases, Musashi-Murayama, Tokyo, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Tse</surname><given-names>Herman</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>The University of Hong Kong, HONG KONG</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>koujikim@med.nagoya-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>e0183453</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Banno et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Banno et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0183453.pdf"/><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Group B streptococci (GBS; Streptococcus agalactiae) are the leading cause of neonatal invasive diseases and are also important pathogens for elderly adults. </plain></SENT>
<SENT sid="3" pm="."><plain>Until now, nearly all GBS with reduced penicillin susceptibility (PRGBS) have shown β-hemolytic activity and grow on sheep blood agar. </plain></SENT>
<SENT sid="4" pm="."><plain>However, we have previously reported three PRGBS clinical isolates harboring a CylK deletion that form small less hemolytic colonies. </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we examined the causes of small, less hemolytic colony formation in these clinical isolates. </plain></SENT>
<SENT sid="6" pm="."><plain>Isogenic strains were sequenced to identify the mutation related to a small colony size. </plain></SENT>
<SENT sid="7" pm="."><plain>We identified a 276_277insG nucleic acid insertion in the thiamin pyrophosphokinase (tpk) gene, resulting in premature termination at amino acid 103 in TPK, as a candidate mutation responsible for small colony formation. </plain></SENT>
<SENT sid="8" pm="."><plain>The recombinant strain Δtpk, which harbored the 276_277insG insertion in the tpk gene, showed small colony formation. </plain></SENT>
<SENT sid="9" pm="."><plain>The recombinant strain ΔcylK, which harbored the G379T substitution in cylK, showed a reduction in hemolytic activity. </plain></SENT>
<SENT sid="10" pm="."><plain>The phenotypes of both recombinant strains were complemented by the expression of intact TPK or CylK, respectively. </plain></SENT>
<SENT sid="11" pm="."><plain>Moreover, the use of Rapid ID 32 API and VITEK MS to identify strains as GBS was evaluated clinical isolates and recombinant strains. </plain></SENT>
<SENT sid="12" pm="."><plain>VITEK MS, but not Rapid ID 32 API, was able to accurately identify the strains as GBS. </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, we determined that mutations in tpk and cylK caused small colonies and reduced hemolytic activity, respectively, and characterized the clinical isolates in detail. </plain></SENT>
</text></SecTag></p></abstract><funding-group><award-group id="award001"><funding-source><institution>the Ministry of Health, Labour and Welfare of Japan</institution></funding-source><award-id>H24-Shinkou-Ippan-010</award-id><principal-award-recipient><name><surname>Arakawa</surname><given-names>Yoshichika</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>the Research Program on Emerging/Re-emerging Infectious Disease Project</award-id><principal-award-recipient><name><surname>Arakawa</surname><given-names>Yoshichika</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by a grant (H24-Shinkou-Ippan-010) from the Ministry of Health, Labour and Welfare of Japan, and was supported in part by the Research Program on Emerging/Re-emerging Infectious Disease Project of Japan Agency for Medical Research and Development, AMED.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec001"><title><text><SENT sid="14" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="15" pm="."><plain>Streptococcus agalactiae (GBS) is the leading cause of neonatal sepsis and meningitis and is responsible for high mortality and morbidity, particularly in neonates and those suffering from underlying medical conditions, such as diabetes [1–3]. β-Lactams are first-line antimicrobial agents for intrapartum antibiotic prophylaxis and the treatment of GBS infections [4, 5]. </plain></SENT>
<SENT sid="16" pm="."><plain>However, GBS clinical isolates with reduced penicillin susceptibility (PRGBS) have emerged via the acquisition of substitutions, including V405A and/or Q557E, in penicillin-binding protein 2X [6–10]. </plain></SENT>
<SENT sid="17" pm="."><plain>PRGBS clinical isolates tend to be non-susceptible or resistant to fluoroquinolones and macrolides [11–13]. </plain></SENT>
<SENT sid="18" pm="."><plain>Most PRGBS clinical isolates show β-hemolytic activity and grow on sheep blood agar. </plain></SENT>
<SENT sid="19" pm="."><plain>However, we previously reported three multidrug-resistant PRGBS clinical isolates (MRY11-004, MRY11-005, and NUBL-2449) that form atypical, small less-β-hemolytic colonies on sheep blood agar [14]. </plain></SENT>
<SENT sid="20" pm="."><plain>These clinical isolates harbor a G379T nucleic acid substitution in the cylK gene, resulting in premature termination at amino acid 127 in CylK, which is required for full hemolytic activity of GBS[14]. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Small colony variants (SCVs) are characterized by reduced growth, small colony size, and atypical colony morphology. </plain></SENT>
<SENT sid="22" pm="."><plain>Additional features, such as decreased respiration, increased resistance to aminoglycosides, reduced fermentation of sugars, and an unstable phenotype are common. </plain></SENT>
<SENT sid="23" pm="."><plain>SCVs are often linked to a deficiency in electron transport or thymidine biosynthesis [15], but the precise causes of small colony formation in other cases are unclear [16–20]. </plain></SENT>
<SENT sid="24" pm="."><plain>Although studies of the morphological and biochemical characteristics of SCVs have been most extensively studied in staphylococci [21–23], SCVs are found in various genera and species, e.g., enterococci [17, 18, 24], Streptococcus pneumoniae [19, 20], Streptococcus tigurinus [16], Escherichia coli [25], and Pseudomonas aeruginosa [15]. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>To our knowledge, there is one report of GBS opacity variants obtained from an unknown number of passages of a clinical isolate [26]. </plain></SENT>
<SENT sid="26" pm="."><plain>However, there are no previous reports of clinical GBS small colony variants. </plain></SENT>
<SENT sid="27" pm="."><plain>In this report, we elucidated the causes of reduced hemolytic activity and small colony formation in three clinical isolates of PRGBS. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec002"><title><text><SENT sid="28" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec id="sec003"><title><text><SENT sid="29" pm="."><plain>Bacterial strains and culture conditions </plain></SENT>
</text></title><p><text><SENT sid="30" pm="."><plain>The three clinical isolates (MRY11-004, MRY11-005, and NUBL2449) were recovered from two patients in one hospital in 2011. </plain></SENT>
<SENT sid="31" pm="."><plain>The first patient was an 88-year-old man who had underlying diseases, including diabetic peripheral neuropathy. </plain></SENT>
<SENT sid="32" pm="."><plain>The isolates were recovered in January of 2011. </plain></SENT>
<SENT sid="33" pm="."><plain>MRY11-004 and MRY11-005 were isolated from his blood and sputum, respectively. </plain></SENT>
<SENT sid="34" pm="."><plain>The second patient was an 83-year-old man. </plain></SENT>
<SENT sid="35" pm="."><plain>NUBL-2449 was isolated from his sputum in November of 2011. </plain></SENT>
<SENT sid="36" pm="."><plain>All three clinical isolates were classified as ST1. </plain></SENT>
<SENT sid="37" pm="."><plain>Moreover, all three clinical isolates showed an identical pulsotype according to PFGE. </plain></SENT>
<SENT sid="38" pm="."><plain>The details of these clinical isolates are described in [14]. </plain></SENT>
</text></p><p><text><SENT sid="39" pm="."><plain>The GBS type V strain ATCC BAA-611 (2603 V/R) and type Ia ATCC BAA-1138 (A909) were used as the parent strains to generate recombinants. </plain></SENT>
<SENT sid="40" pm="."><plain>The GBS recombinant strain ΔcylK was based on ATCC BAA-611, harboring the G379T substitution in cylK, resulting in premature termination at amino acid 127 in CylK. </plain></SENT>
<SENT sid="41" pm="."><plain>The GBS recombinant strain Δtpk was based on ATCC BAA-1138, harboring the 276_277insG insertion in tpk, resulting in premature termination at amino acid 103 in thiamin pyrophosphokinase (TPK), which catalyzes the direct phosphorylation of thiamin via ATP to form thiamin pyrophosphate (TPP). </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>GBS was cultivated in Todd–Hewitt broth (THB) (BD, Franklin Lakes, NJ, USA) and Todd–Hewitt agar (THA) at 37°C in 5% CO2. </plain></SENT>
<SENT sid="43" pm="."><plain>GBS strains carrying recombinant pG+host6 or pDL278 derivatives were grown in the presence of erythromycin (5 μg/ml), chloramphenicol (10 μg/ml), and/or spectinomycin (300 μg/ml). </plain></SENT>
<SENT sid="44" pm="."><plain>Cultivation of Δtpk was performed at 37°C in 5% CO2 in THB and on THA containing TPP (500 μg/L). E. coli DH10B was grown at 37°C in LB broth and strains carrying recombinant pG+host6 or pDL278 derivatives were selected in the presence of ampicillin (200 μg/ml) and spectinomycin (200 μg/ml). </plain></SENT>
</text></p></sec><sec id="sec004"><title><text><SENT sid="45" pm="."><plain>Next-generation sequencing and analysis </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>Bacteria were cultured overnight at 37°C in 5% CO2, and chromosomal DNA was extracted using the QIAamp® DNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol, with slight modifications in order to completely remove RNA. </plain></SENT>
<SENT sid="47" pm="."><plain>The overnight culture (1 mL) was centrifuged for 10 min at 3,000 × g, and the supernatant was removed. </plain></SENT>
<SENT sid="48" pm="."><plain>The pellet was resuspended in 200 μL of the suspension solution and then incubated at 37°C for 90 min. </plain></SENT>
<SENT sid="49" pm="."><plain>Then, 20 μL of proteinase K was added, and the solution was incubated for 60 min at 57°C, until it became clear. </plain></SENT>
<SENT sid="50" pm="."><plain>RNase A (4 μL) was added, and the solution was incubated for 5 min at 25°C. </plain></SENT>
<SENT sid="51" pm="."><plain>DNA was then purified following the QIAamp DNA Kit protocol. </plain></SENT>
<SENT sid="52" pm="."><plain>Concentrations of extracted DNA were measured using both NanoDrop and QuBit fluorometric quantitation. </plain></SENT>
<SENT sid="53" pm="."><plain>Extracted DNA was then prepared for next-generation sequencing using the Nextera® XT DNA Preparation Kit. </plain></SENT>
<SENT sid="54" pm="."><plain>Sequencing was performed using a MiSeq sequencer (Illumina, San Diego, CA, USA) with the MiSeq Reagent Kit v3 (2 × 300 mer). </plain></SENT>
<SENT sid="55" pm="."><plain>Paired-end sequencing data from the MiSeq reporter software were further analyzed using CLC genomics Workbench ver. </plain></SENT>
<SENT sid="56" pm="."><plain>9 (CLC Bio). </plain></SENT>
</text></p></sec><sec id="sec005"><title><text><SENT sid="57" pm="."><plain>Construction of ΔcylK and a complementation plasmid to express intact CylK in ΔcylK </plain></SENT>
</text></title><p><text><SENT sid="58" pm="."><plain>pG+host6-ΔcylK was constructed to introduce the G379T substitution into cylK. </plain></SENT>
<SENT sid="59" pm="."><plain>The plasmid was comprised of a thermosensitive plasmid pG+host6 backbone, with a fragment of the cylK gene containing the G379T substitution (nucleotide positions 659180 to 659657 in the GBS ATCC BAA-611 genome), the chloramphenicol acetyltransferase gene, conferring resistance to chloramphenicol, and a fragment of DNA from the region directly downstream of the cylK gene (nucleotide positions 659073 to 659648 in the GBS ATCC BAA-611 genome). </plain></SENT>
<SENT sid="60" pm="."><plain>These fragments were amplified by PCR using primers listed in S1 Table. </plain></SENT>
<SENT sid="61" pm="."><plain>Then, pG+host6-ΔcylK was transformed into E. coli DH10B for amplification. </plain></SENT>
<SENT sid="62" pm="."><plain>The purified plasmid was transformed into GBS BAA-611 and the transformants were selected on THA containing 0.5 μg/ml erythromycin at 30°C. </plain></SENT>
<SENT sid="63" pm="."><plain>Successful integrant strains were then cultivated for 3 days in THB at 30°C without erythromycin selection to facilitate the excision of the vector pG+host6-ΔcylK [27]. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>The pCylK plasmid was constructed to express full-length CylK in ΔcylK. </plain></SENT>
<SENT sid="65" pm="."><plain>pCylK was comprised of the E. coli-GBS shuttle vector plasmid pDL278 backbone, with a fragment of the promoter region from the bca gene (nucleotide positions 459015 to 459255 in the GBS ATCC BAA-1138 genome) and the full-length cylK gene (nucleotide positions 459015 to 459255 in the GBS ATCC BAA-611 genome) [28, 29]. </plain></SENT>
<SENT sid="66" pm="."><plain>The pCylK plasmid was transformed into E. coli DH10B for amplification. </plain></SENT>
<SENT sid="67" pm="."><plain>The purified plasmid was transformed into ΔcylK and the transformants were selected on THA containing 300 μg/ml spectinomycin. </plain></SENT>
</text></p></sec><sec id="sec006"><title><text><SENT sid="68" pm="."><plain>Construction of Δtpk and a complementation plasmid to express intact TPK in Δtpk </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>Δtpk was constructed using a similar method to that used for the construction of ΔcylK, with minor modifications. </plain></SENT>
<SENT sid="70" pm="."><plain>pG+host6-Δtpk was constructed in order to introduce the 276_277insG insertion in tpk. </plain></SENT>
<SENT sid="71" pm="."><plain>The plasmid was comprised of a thermosensitive plasmid pG+host6 backbone, with a fragment of the tpk gene containing the 276_277insG insertion (nucleotide positions 1790161 to 1790826 in the GBS ATCC BAA-1138 genome), the chloramphenicol acetyltransferase gene, and a fragment of DNA from the region directly downstream of the tpk gene (nucleotide positions 1789494 to 1790190 in the GBS ATCC BAA-1138 genome). </plain></SENT>
<SENT sid="72" pm="."><plain>Integrant strains were successively cultivated for 3 days in THB containing TPP (500 μg/L) at 30°C without erythromycin selection to facilitate the excision of vector pG+host6-Δtpk. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>The pTPK plasmid was constructed to express full-length TPK in Δtpk. </plain></SENT>
<SENT sid="74" pm="."><plain>pTPK was comprised of the E. coli-GBS shuttle vector plasmid pDL278 backbone, with a fragment of the promoter region from the bca gene (nucleotide positions 459015 to 459255 in the GBS ATCC BAA-1138 genome), and the full-length tpk gene (nucleotide positions 1790174 to 1790806 in the GBS ATCC BAA-1138 genome). </plain></SENT>
<SENT sid="75" pm="."><plain>pTPK was transformed into E. coli DH10B for amplification. </plain></SENT>
<SENT sid="76" pm="."><plain>The purified plasmid was transformed into Δtpk and MRY11-004. </plain></SENT>
<SENT sid="77" pm="."><plain>Thereafter, transformants were selected on THA containing 300 μg/ml spectinomycin at 37°C. </plain></SENT>
</text></p></sec><sec id="sec007"><title><text><SENT sid="78" pm="."><plain>Growth curve </plain></SENT>
</text></title><p><text><SENT sid="79" pm="."><plain>Bacterial growth in THB at 37°C in ambient air was monitored using an OD monitor (ODBox-C; TAITEC, Koshigaya, Japan). </plain></SENT>
<SENT sid="80" pm="."><plain>Overnight culture (60 μL) was diluted in 6 mL of fresh THB. </plain></SENT>
<SENT sid="81" pm="."><plain>The cultures were shaken at 160 rpm and the optical density (600 nm) was measured every 5 min for 24 h. </plain></SENT>
<SENT sid="82" pm="."><plain>The experiment was performed five times. </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="83" pm="."><plain>Transmission electron microscopy </plain></SENT>
</text></title><p><text><SENT sid="84" pm="."><plain>For transmission electron microscopy (TEM) analyses, BAA-1138 and Δtpk cultures were incubated for 12 h in THB and THB containing TPP (500 μg/L), respectively. </plain></SENT>
<SENT sid="85" pm="."><plain>MYR11-004 and Δtpk cultures were also incubated for 12 h in THB containing no TPP. </plain></SENT>
<SENT sid="86" pm="."><plain>After washing with PBS (0.1 M Phosphate Buffer Solution, pH 7.4) three times, bacterial cells were washed in PBS containing 2% glutaraldehyde and then stored at 4°C overnight. </plain></SENT>
<SENT sid="87" pm="."><plain>Bacterial cell pellets were washed with PBS four times, resuspended in PBS containing 2% osmium tetroxide, and incubated at 4°C for 2 h. </plain></SENT>
<SENT sid="88" pm="."><plain>Samples were cut using an ultramicrotome. </plain></SENT>
<SENT sid="89" pm="."><plain>TEM was performed using the JEM-1400PLUS (JEOL, Tokyo, Japan). </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="90" pm="."><plain>Rapid ID 32 API and VITEK MS assay </plain></SENT>
</text></title><p><text><SENT sid="91" pm="."><plain>Clinical isolates, Δtpk, and BAA-1138 were analyzed using Rapid ID 32 API (bioMérieux, Marcy-l'Étoile, France) and VITEK MS (Sysmex bioMérieux) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="92" pm="."><plain>The three clinical isolates and Δtpk were cultured on sheep blood agar (Nissui, Tokyo, Japan) for 3 days and on chocolate II agar (BD) in 5% CO2 overnight. </plain></SENT>
<SENT sid="93" pm="."><plain>BAA-1138 cultured on sheep blood agar and on chocolate II agar in 5% CO2 overnight was also analyzed. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="94" pm="."><plain>Nucleotide sequence accession numbers </plain></SENT>
</text></title><p><text><SENT sid="95" pm="."><plain>Raw sequence data from Miseq sequencing are deposited as fastq files at EMBL/GenBank under the accession numbers SAMD00077745, SAMD00077746, SAMD00077747, SAMD00077757, SAMD00077758 and SAMD00077759 for MRY11-004, MRY11-005, NUBL-2449, MRY11-004L, MRY11-005L and NUBL-2449L, respectively. </plain></SENT>
<SENT sid="96" pm="."><plain>The raw sequencing data have been deposited in the DDBJ Sequence Read Archive (DRA) under accession numbers DRA005682, DRA005683, DRA005684, DRA005686, DRA005687, and DRA005688 for MRY11-004, MRY11-005, NUBL-2449, MRY11-004L, MRY11-005L, and NUBL-2449L, respectively [30]. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="97" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="98" pm="."><plain>Growth curve data are expressed as means ± standard deviation. </plain></SENT>
<SENT sid="99" pm="."><plain>The statistical significance (P-values) of differences in mean values for two-sample comparisons was determined using the Student's t-test implemented in Microsoft Excel. P &lt; 0.05 indicated statistical significance [31]. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec012"><title><text><SENT sid="100" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec013"><title><text><SENT sid="101" pm="."><plain>Phenotypes of the ΔcylK strain </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>To determine if ΔcylK causes reduced hemolytic activity and/or small colony formation, we constructed ΔcylK based on BAA-611 harboring the G379T substitution in cylK gene. </plain></SENT>
<SENT sid="103" pm="."><plain>The recombinant strain showed less β-hemolytic activity than that of the wild-type strain on sheep blood agar plates. </plain></SENT>
<SENT sid="104" pm="."><plain>However, ΔcylK did not show small colony formation (Fig 1). </plain></SENT>
<SENT sid="105" pm="."><plain>The mutant was then complemented with a plasmid harboring cylK and the resulting strain showed similar hemolytic activity to that of the wild type on sheep blood agar plates (S1 Fig). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0183453.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="106" pm="."><plain>Comparison of hemolytic activity and colony formation to elucidate influence of deletion CylK. </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>Colony size and hemolytic activity of a GBS ATCC strain (BAA-611), recombinant strains (ΔcylK), and complemented strains (ΔcylK+ pDL278 and ΔcylK+pCylK) on 5% sheep blood agar. </plain></SENT>
<SENT sid="108" pm="."><plain>The strains were grown at 37°C in 5% CO2 for 16 h. ΔcylK is a recombinant strain based on ATCC BAA-611, harboring the G379T substitution in cylK, resulting in premature termination at amino acid 127 in CylK. </plain></SENT>
<SENT sid="109" pm="."><plain>pDL278 is a gram-positive and gram-negative shuttle vector. </plain></SENT>
<SENT sid="110" pm="."><plain>pCylK is a complementation plasmid used to express intact TPK in the ΔcylK strain. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0183453.g001"/></fig></SecTag></sec><sec id="sec014"><title><text><SENT sid="111" pm="."><plain>Identification of the cause of small colony formation and phenotypes of the Δtpk strain </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>After several in vitro passages on 5% sheep blood agar, three clinical isolates reverted to a fast-growing phenotype and large colony size, equal to that of the GBS ATCC strains (approximately 1 mm in diameter). </plain></SENT>
<SENT sid="113" pm="."><plain>Large colonies were confirmed to be GBS using the agglutination method with anti-Lancefield B antigen serum and serotype VIII with anti-GBS serotype-specific serum, and these results were identical to those obtained for clinical isolates. </plain></SENT>
<SENT sid="114" pm="."><plain>To identify a causal genetic factor for the observed differences, the whole genomes of the clinical isolates and the derivative strains were sequenced. </plain></SENT>
<SENT sid="115" pm="."><plain>Genomes were compared using CLC Workbench ver. </plain></SENT>
<SENT sid="116" pm="."><plain>9 to detect single nucleotide polymorphisms (SNPs). </plain></SENT>
<SENT sid="117" pm="."><plain>Although several SNPs were found in comparisons between the clinical isolates and derivative strains (Table 1), only the 276_277insG insertion in the tpk gene was found in all three clinical isolates. </plain></SENT>
<SENT sid="118" pm="."><plain>This insertion was confirmed using Sanger sequencing, and caused premature termination at amino acid 103 in TPK. </plain></SENT>
<SENT sid="119" pm="."><plain>To determine the effects of this insertion, we constructed the Δtpk recombinant strain based on S. agalactiae ATCC BAA-1138 harboring the 276_277insG insertion in the tpk gene. </plain></SENT>
<SENT sid="120" pm="."><plain>The Δtpk strain showed similar hemolytic activity on sheep blood agar to that of the wild-type strain (S1 Fig) and smaller colonies (less than 1 mm in diameter) than those of the wild-type strain (approximately 1 mm in diameter) on sheep blood agar (Fig 2). </plain></SENT>
<SENT sid="121" pm="."><plain>Moreover, when a plasmid expressing full-length TPK was introduced into Δtpk and MRY11-004, the resulting strain showed similar colony formation to that of the wild-type strain on sheep blood agar (Fig 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0183453.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="122" pm="."><plain>Nucleic acid differences between MRY11-004 and MRY11-004L, MRY11-005 and MRY11-005L, NUBL-2449 and NUBL-2449L using CLC workbench ver. </plain></SENT>
<SENT sid="123" pm="."><plain>9 (&gt;80%; Frequency). </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0183453.t001g" xlink:href="pone.0183453.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" colspan="2" rowspan="1"><text><SENT sid="124" pm="."><plain>Nucleic acid difference </plain></SENT>
</text></th><th align="center" rowspan="2" colspan="1"><text><SENT sid="125" pm="."><plain>Position </plain></SENT>
</text></th><th align="center" rowspan="2" colspan="1"><text><SENT sid="126" pm="."><plain>Effect (length with the insertion or deletion/full length of the gene) </plain></SENT>
</text></th><th align="center" rowspan="2" colspan="1"><text><SENT sid="127" pm="."><plain>Gene description (Locus tag) </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>MRY11-004 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>MRY11-004L </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>276_277 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>Frameshift (102/210) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>thiamine pyrophosphokinase (SAG1775) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>78 bases upstream of SAG2072 (78 bases upstream of SAG2073) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>uridine phosphorylase (SAG2072) (GntR family transcriptional regulator (SAG2073)) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>226_227 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Frameshift (80/515) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Phosphoribosyl aminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase (SAG0030) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>341_342 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Frameshift (115/1275) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>Mannosyl-glycoprotein endo-β-N-acetylglucosaminidase (EN73_03515) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>MRY11-005 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>MRY11-005L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>276_277 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>Frameshift (102/210) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>thiamine pyrophosphokinase (SAG1775) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>NUBL2449 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>NUBL2449L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>276_277 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Frameshift (102/210) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>thiamine pyrophosphokinase (SAG1775) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>279 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>thiamine pyrophosphokinase (SAG1775) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>1442_1443 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>Frameshift (501/692) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>elongation factor G (SAG1769) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="173" pm="."><plain>The strains MRY11-004L, MRY11-005L, and NUBL2449L are large colony strains derived from their parental clinical small colony strains MRY11-004, MRY11-005, and NUBL2449, respectively, after several passages on sheep blood agar.–indicates a deletion. </plain></SENT>
<SENT sid="174" pm="."><plain>Position is defined as the distance from the start codon. </plain></SENT>
<SENT sid="175" pm="."><plain>Frequency = Count (detected specific nucleic acids at a nucleic acid position)/Coverage (all nucleic acids at a certain nucleic acid position). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="pone.0183453.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="176" pm="."><plain>Comparison of hemolytic activity and colony formation to elucidate influence of deletion TPK. </plain></SENT>
</text></title><p><text><SENT sid="177" pm="."><plain>Colony morphology of BAA-1138, Δtpk, Δtpk+pDL278, and Δtpk+pTPK grown on sheep blood agar. </plain></SENT>
<SENT sid="178" pm="."><plain>BAA-1138 and Δtpk+pTPK were grown at 37°C in 5% CO2 for 16 h. Δtpk and Δtpk+pDL278 were grown at 37°C in 5% CO2 for 72 h. Δtpk is a recombinant strain based on ATCC BAA-1138, harboring the 276_277insG insertion in tpk, resulting in a deletion in premature termination at amino acid 103 in thiamin pyrophosphokinase (TPK). </plain></SENT>
<SENT sid="179" pm="."><plain>pDL278 is a gram-positive and gram-negative shuttle vector. </plain></SENT>
<SENT sid="180" pm="."><plain>pTPK is a complementation plasmid used to express intact TPK in the Δtpk strain. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0183453.g002"/></fig></SecTag></sec><sec id="sec015"><title><text><SENT sid="181" pm="."><plain>Comparative analysis of growth characteristics </plain></SENT>
</text></title><p><text><SENT sid="182" pm="."><plain>We monitored the growth of the clinical isolates GBS ATCC strain BAA-1138, Δtpk, Δtpk+pDL278, and Δtpk+pTPK. </plain></SENT>
<SENT sid="183" pm="."><plain>The GBS ATCC BAA-1138, Δtpk+pTPK, and Δtpk supplemented with TPP (500 μg/L) had similar growth profiles. </plain></SENT>
<SENT sid="184" pm="."><plain>However, the clinical isolates Δtpk and Δtpk+pDL278 displayed significantly reduced growth compared with that of the GBS ATCC strain BAA-1138, Δtpk supplemented with TPP (500 μg/L), and Δtpk+pTPK (Fig 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0183453.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="185" pm="."><plain>Comparison of growth rate of GBS ATCC strain, recombinant strain and complemented strains. </plain></SENT>
</text></title><p><text><SENT sid="186" pm="."><plain>Growth curves (OD600nm) of the clinical isolates (MRY11-004, MRY11-005, and NUBL-2449), GBS ATCC strain (BAA-1138), recombinant strain (Δtpk), and complemented strains (Δtpk+pDL278 and Δtpk+pTPK) at 37°C in ambient air (A,B). </plain></SENT>
<SENT sid="187" pm="."><plain>OD600nm = 0–2.5 (A), OD600nm = 0–0.2 (B). </plain></SENT>
<SENT sid="188" pm="."><plain>Data are presented as averages of five independent experiments. </plain></SENT>
<SENT sid="189" pm="."><plain>Data are the mean ± standard deviation OD600nm. *,**Statistically significant difference: *P &lt; 0.05; **P &lt; 0.01. Δtpk indicates a recombinant strain based on ATCC BAA-1138, harboring the 276_277insG insertion in tpk, resulting in premature termination at amino acid 103 in thiamin pyrophosphokinase (TPK). </plain></SENT>
<SENT sid="190" pm="."><plain>pDL278 is a gram-positive and gram-negative shuttle vector. </plain></SENT>
<SENT sid="191" pm="."><plain>pTPK is a complementation plasmid used to express intact TPK in the Δtpk strain. Δtpk+TPP indicates Δtpk grown in Todd–Hewitt broth containing thiamine pyrophosphate (500 μg/L). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0183453.g003"/></fig></SecTag></sec><sec id="sec016"><title><text><SENT sid="192" pm="."><plain>Auxotrophic testing </plain></SENT>
</text></title><p><text><SENT sid="193" pm="."><plain>The clinical isolates and Δtpk showed similar colony sizes to those of GBS ATCC strains on sheep blood agar, MHA, and THA containing greater than 50 μg/L TPP. </plain></SENT>
<SENT sid="194" pm="."><plain>Additionally, similar to A909, these isolates grew on sheep blood agar around discs containing 20 μg of TPP. </plain></SENT>
<SENT sid="195" pm="."><plain>However, on MHA with 5% sheep blood and sheep blood agar around discs with 20 μg of thymidine, Δtpk showed medium colony sizes (1 mm in diameter), which were smaller than those of GBS ATCC strains (Fig 4). </plain></SENT>
<SENT sid="196" pm="."><plain>Moreover, THA containing more than 50 μg/ml thymidine showed medium-sized colonies. </plain></SENT>
<SENT sid="197" pm="."><plain>Although previous reports have shown that the addition of NAD+, menadione, thiamine, or hemin results in a normal colony morphology in S. aureus SCVs, the clinical isolates and Δtpk did not show visible growth around discs containing 20 μg of these compounds[15] [21] [22]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0183453.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="198" pm="."><plain>Comparison of auxotrophy of GBS ATCC strain, recombinant strain and complemented strains. </plain></SENT>
</text></title><p><text><SENT sid="199" pm="."><plain>Colony morphology of the clinical isolate MRY11-004 (A–D) and recombinant strain Δtpk (E–H) grown on sheep blood agar plate (A, B, E, F) and Mueller Hinton Agar with 5% sheep blood (C, D, G, H) after incubation in 5% CO2 overnight. </plain></SENT>
<SENT sid="200" pm="."><plain>In B, D, F, and H, the left disc contained 20 μg of thymidine (thy) and the right disc contained 20 μg of thiamin pyrophosphate (TPP). </plain></SENT>
<SENT sid="201" pm="."><plain>In A, C, E, and G, both the left and right discs were empty (E). Δtpk is a recombinant strain based on ATCC BAA-1138, harboring the 276_277insG insertion in the thiamin pyrophosphokinase (tpk) gene, resulting in premature termination at amino acid 103 in TPK. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0183453.g004"/></fig></SecTag><p><text><SENT sid="202" pm="."><plain>While the clinical isolates and Δtpk were able to grow on chocolate II agar, they showed medium colony sizes on BY chocolate agar. </plain></SENT>
<SENT sid="203" pm="."><plain>A comparison of the ingredients in these agars revealed that chocolate II agar contained 10 mg/L hemoglobin, while BY chocolate agar contained 5% horse blood. </plain></SENT>
<SENT sid="204" pm="."><plain>Accordingly, the hemoglobin content may explain the growth of the clinical isolates and Δtpk. </plain></SENT>
<SENT sid="205" pm="."><plain>Supplementation of MHA and THA with 10 mg/mL hemoglobin confirmed this hypothesis; the clinical isolates and Δtpk showed colony sizes similar to those of the ATCC strain. </plain></SENT>
</text></p></sec><sec id="sec017"><title><text><SENT sid="206" pm="."><plain>TEM analyses </plain></SENT>
</text></title><p><text><SENT sid="207" pm="."><plain>BAA-1138 and Δtpk containing TPP (500 μg/L) exhibited regular cell division with single cross walls in dividing cells. </plain></SENT>
<SENT sid="208" pm="."><plain>However, cell division in MRY11-004 and Δtpk appeared to terminate before the cells could fully separate and show agglutination. </plain></SENT>
<SENT sid="209" pm="."><plain>Moreover, only MRY11-004 showed heterogeneous cell sizes and cell clusters (Fig 5). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0183453.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183453.g005</object-id><label>Fig 5</label><caption><title><text><SENT sid="210" pm="."><plain>Comparison of TEM analysis of GBS ATCC strain, recombinant strain and complemented strains. </plain></SENT>
</text></title><p><text><SENT sid="211" pm="."><plain>TEM of BAA-1138 (A and F), Δtpk with TPP 500 μg/L (B and G), Δtpk (C and H), and MRY11-004 (D, E and I). </plain></SENT>
<SENT sid="212" pm="."><plain>Bars: 200 nm (A–E). </plain></SENT>
<SENT sid="213" pm="."><plain>Bars: 1 μm (F–I) Δtpk is a recombinant strain based on ATCC BAA-1138, harboring the 276_277insG insertion in tpk, resulting in premature termination at amino acid 103 in thiamin pyrophosphokinase. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0183453.g005"/></fig></SecTag></sec><sec id="sec018"><title><text><SENT sid="214" pm="."><plain>Identification by Rapid ID 32 Strep API and VITEK MS </plain></SENT>
</text></title><p><text><SENT sid="215" pm="."><plain>Although the clinical isolates and BAA-1138 were identified as GBS using the Rapid ID 32 Strep API system, Δtpk cultured on sheep blood was not identified as GBS and was judged as SDSE or GBS. </plain></SENT>
<SENT sid="216" pm="."><plain>Concerning biological profiles, the clinical isolates showed different trehalose (TRE), pullulan (PUL), sodium pyruvate (VP), and maltose (MAL) phenotypes compared to those of BAA-1138. </plain></SENT>
<SENT sid="217" pm="."><plain>Moreover, in addition to PUL, VP, and MAL, Δtpk showed different sucrose (SAC) phenotypes. </plain></SENT>
<SENT sid="218" pm="."><plain>Therefore, Δtpk was unable to be correctly confirmed as GBS. </plain></SENT>
<SENT sid="219" pm="."><plain>However, the clinical isolates, Δtpk, and BAA-1138 cultured on sheep blood and chocolate II agar were identified as GBS (99.9% identity) using VITEK MS. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec019"><title><text><SENT sid="220" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="221" pm="."><plain>We characterized the first clinical PRGBS with less hemolytic activity and auxotrophy for TPP. </plain></SENT>
<SENT sid="222" pm="."><plain>The G379T substitution in cylK gene and 276_277insG insertion in tpk gene caused the less hemolytic activity and small colony formation, respectively. </plain></SENT>
<SENT sid="223" pm="."><plain>In previous reports, SCVs with electron transport and thymidine biosynthesis defects have shown both small colony formation and low hemolytic activity due to the deletion of a single gene. </plain></SENT>
<SENT sid="224" pm="."><plain>However, in this study, small colony formation and reduced hemolytic activity were caused by different genes. </plain></SENT>
<SENT sid="225" pm="."><plain>The deletion of CylK results in reduced hemolytic activity on horse blood agar and similar growth to that of the parental strain in THB supplemented with 5% yeast extract [32, 33]. </plain></SENT>
<SENT sid="226" pm="."><plain>This suggests that full-length CylK is required for full hemolytic activity of GBS, and may not be related to cell growth and colony size. </plain></SENT>
<SENT sid="227" pm="."><plain>The G379T substitution in cylK, resulting in premature termination at amino acid 127 in CylK, was associated with low hemolytic activity. </plain></SENT>
<SENT sid="228" pm="."><plain>The deletion of amino acids 22 to 115 of CylK have been reported to cause reduced hemolytic activity [32]. </plain></SENT>
<SENT sid="229" pm="."><plain>Therefore, full-length CylK might be required for full hemolytic activity in GBS. </plain></SENT>
<SENT sid="230" pm="."><plain>In the TEM analysis, a clinical isolate showed heterogeneous cell sizes and cell clusters; however, there are many candidate loci associated with this heterogeneity based on next-generation sequence data for the three clinical isolates and therefore the underlying causes are unknown. </plain></SENT>
</text></p><p><text><SENT sid="231" pm="."><plain>The Δtpk strain, which exhibited premature termination at amino acid 103 in TPK, showed small colony formation. </plain></SENT>
<SENT sid="232" pm="."><plain>Moreover, complementation of the strain with a plasmid harboring full-length TPK resulted in similar colony sizes to those of GBS ATCC strains. </plain></SENT>
<SENT sid="233" pm="."><plain>Therefore, the function of this domain is related to growth. </plain></SENT>
<SENT sid="234" pm="."><plain>The structure of TPK in yeast bound with TPP has revealed the locations of the thiamin-binding site and probable catalytic residue [34]. </plain></SENT>
<SENT sid="235" pm="."><plain>Analysis of GBS TPK using Pfam showed that these sites were conserved. </plain></SENT>
<SENT sid="236" pm="."><plain>Therefore, because amino acid positions 103–210 in TPK correspond to the thiamine-binding domain, Δtpk and clinical isolates lacking these amino acids might not bind thiamine and accordingly might be unable to catalyze the production of TPP. </plain></SENT>
<SENT sid="237" pm="."><plain>Moreover, because TPP, a coenzyme form of vitamin B1, is important for the formation of a coenzyme required for central metabolic functions (pyruvate decarboxylase, pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase), TPP might be essential for cell growth in bacteria and Δtpk might exhibit growth defects [35]. </plain></SENT>
<SENT sid="238" pm="."><plain>Moreover, in Schizosaccharomyces pombe, tnr3-recombinant strains (low-expressed TPK) grow slowly and show aberrant morphology [36]. </plain></SENT>
<SENT sid="239" pm="."><plain>The TPK deletion has not been detected in bacterial clinical isolates; therefore, these are the first known clinical isolates with the 276_277insG insertion in the tpk gene. </plain></SENT>
</text></p><p><text><SENT sid="240" pm="."><plain>The three clinical isolates analyzed in this study somewhat resemble previously reported SCVs. </plain></SENT>
<SENT sid="241" pm="."><plain>However, they also have different characteristics from previously reported SCVs. </plain></SENT>
<SENT sid="242" pm="."><plain>The three clinical isolates showed slow growth phenotypes on THA, sheep blood agar, and in THB. </plain></SENT>
<SENT sid="243" pm="."><plain>This phenotype resembles that of previously reported SCVs [15–18, 24]. </plain></SENT>
<SENT sid="244" pm="."><plain>However, the clinical isolates in this study did not show irregular cell shapes, as observed in other SCVs, when analyzed by TEM [17, 18], nor did they show auxotrophy for menadione, hemine, or thiamine, as did SCVs of S. aureus. </plain></SENT>
<SENT sid="245" pm="."><plain>The clinical isolates and Δtpk showed auxotrophy for TPP. </plain></SENT>
<SENT sid="246" pm="."><plain>Moreover, small colony formation was caused by a partial deletion in the TPK, which has not been reported in other SCVs to date. </plain></SENT>
<SENT sid="247" pm="."><plain>In general, electron transport deficient-SCVs and thymidine biosynthesis deficient-SCVs show an increase in gentamicin and sulfamethoxazole/trimethoprim MIC, respectively. </plain></SENT>
<SENT sid="248" pm="."><plain>Although the three clinical isolates showed resistance to sulfamethoxazole/trimethoprim (MIC, &gt;256 μg/ml), there was no difference observed in the MIC of gentamicin for the clinical isolate MRY11-004 (MIC 32 μg/ml) compared to those of MRY11-004+pTPK (MIC 32 μg/ml, expressing full-length TPK in MRY11-004), Δtpk (MIC 64 μg/ml), and Δtpk +pTPK (MIC 64 μg/ml). </plain></SENT>
<SENT sid="249" pm="."><plain>Furthermore, SCVs are typically isolated from patients undergoing long-term antibiotic therapy, and can cause latent or recurrent infections [15]. </plain></SENT>
<SENT sid="250" pm="."><plain>For the three clinical isolates, sulbactam/ampicillin therapy was documented from October 25 to October 31 and from November 28 to December 2 in 2010. </plain></SENT>
<SENT sid="251" pm="."><plain>Thereafter, two of the clinical isolates (MRY11-004 and MRY11-005) were isolated from sputum and blood on January 4, 2011. </plain></SENT>
<SENT sid="252" pm="."><plain>Moreover, piperacillin/tazobactam and levofloxacin therapy was documented from October 22 to October 25 and from November 27 to November 31 in 2010, respectively. </plain></SENT>
<SENT sid="253" pm="."><plain>The clinical isolate NUBL-2449 was isolated from sputum on November 14, 2012 [14]. </plain></SENT>
<SENT sid="254" pm="."><plain>Therefore, no cases of long-term antibiotic therapy were documented in the two patients, and this likely does not explain the small colony formation phenotype. </plain></SENT>
<SENT sid="255" pm="."><plain>On the other hand, these β-lactam and quinolone therapies might have selected for multidrug resistance and/or PRGBS. </plain></SENT>
<SENT sid="256" pm="."><plain>Selection for PRGBS by long-term β-lactam therapy has been observed [9]. </plain></SENT>
<SENT sid="257" pm="."><plain>Additionally, conventional identification systems (e.g., the API Rapid system) have failed to identify E. coli, E. faecium, and E. faecalis SCVs correctly [18, 24, 25]. </plain></SENT>
<SENT sid="258" pm="."><plain>Although the clinical isolates cultured on chocolate II agar and sheep blood agar could be detected using the Rapid ID 32 Strep API system, Δtpk on sheep blood agar yielded no definitive results owing to an inconsistent biological phenotype. </plain></SENT>
<SENT sid="259" pm="."><plain>Furthermore, several biochemical phenotypes were different from those of the parental strain and GBS ATCC strains. </plain></SENT>
<SENT sid="260" pm="."><plain>Therefore, clinical isolates of GBS with deletions in the tpk gene might be misidentified in the future. </plain></SENT>
<SENT sid="261" pm="."><plain>In contrast to conventional identification systems based on biochemical characteristics, the clinical isolates and Δtpk were correctly identified by VITEK MS (99.9% identity). </plain></SENT>
<SENT sid="262" pm="."><plain>Moreover, E. faecium SCVs were precisely identified by VITEK MS [18]. </plain></SENT>
<SENT sid="263" pm="."><plain>These findings suggest that MALDI-TOF MS is a powerful tool for the identification of strains with similar atypical phenotypes. </plain></SENT>
</text></p><p><text><SENT sid="264" pm="."><plain>In conclusion, we characterized the first PRGBS clinical isolates with reduced hemolytic activity and auxotrophy for TPP. </plain></SENT>
<SENT sid="265" pm="."><plain>Moreover, we found that VITEK MS correctly identified GBS with a deletion in TPK. </plain></SENT>
<SENT sid="266" pm="."><plain>In this study, we revealed the causes of small colony formation with less hemolytic activity and characterized clinical isolates in detail. </plain></SENT>
<SENT sid="267" pm="."><plain>Because these clinical isolates may be misclassified using routine bacterial tests and are multidrug resistant, they represent a potential public health concern. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec020"><title><text><SENT sid="268" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0183453.s001"><label>S1 Fig</label><caption><title><text><SENT sid="269" pm="."><plain>Comparison of hemolytic activity of clinical isolates, recombinant strains and complemented strains. </plain></SENT>
</text></title><p><text><SENT sid="270" pm="."><plain>Clinical isolates(MRY11-004, MRY11-005 and NUBL-2449), recombinant strains(ΔcylK and Δtpk) and complemented strains (ΔcylK+pDL278, ΔcylK+pCylK, Δtpk+pTPK and Δtpk+pTPK) on Mueller Hinton Agar with 5% Sheep Blood. ΔcylK indicates a recombinant strain based on ATCC BAA-611, harbouring the G379T substitution in cylK, resulting in premature termination at amino acid 127 in CylK. </plain></SENT>
<SENT sid="271" pm="."><plain>pDL278 is a Gram-positive and gram-negative shuttle vector. ΔcylK+pCylK indicates a complementation plasmid to express intact TPK in ΔcylK strain.Δtpk indicates a recombinant strain based on ATCC BAA-1138, harbouring the 276_277insG insertion in tpk, resulting in premature termination at amino acid 103 in thiamin pyrophosphokinase. Δtpk+pTPK indicates a complementation plasmid to express intact TPK in Δtpk strain. </plain></SENT>
<SENT sid="272" pm="."><plain>A: MRY11-004 B: MRY11-005 C: NUBL-2449 D: 2603 V/R E; ΔcylK F: ΔcylK +pDL278 G: ΔcylK+CylK H: ΔcylK+pCylK I: A909 J; Δtpk K: Δtpk+pDL278 L; Δtpk+pTPK. </plain></SENT>
</text></p><p><text><SENT sid="273" pm="."><plain>(TIFF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0183453.s001.tiff"><caption><p><text><SENT sid="274" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183453.s002"><label>S1 Table</label><caption><title><text><SENT sid="275" pm="."><plain>Primers used for PCR amplification in this study. </plain></SENT>
</text></title><p><text><SENT sid="276" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0183453.s002.docx"><caption><p><text><SENT sid="277" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="278" pm="."><plain>We wish to acknowledge the Division for Medical Research Engineering, Nagoya University Graduate School of Medicine, for assistance with MiSeq experiments, CLC Genomics Workbench ver. </plain></SENT>
<SENT sid="279" pm="."><plain>9, and TEM. </plain></SENT>
<SENT sid="280" pm="."><plain>We also thank Takuya Hattori (Department of Clinical Laboratory, Japanese Red Cross Nagoya Daiichi Hospital) for VITEK MS experiments. </plain></SENT>
<SENT sid="281" pm="."><plain>This manuscript was edited by Editage, a professional language-editing company. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0183453.ref001"><text><SENT sid="282" pm="."><plain>1LamagniTL, KeshishianC, EfstratiouA, GuyR, HendersonKL, BroughtonK, et al Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010. Clin Infect Dis. 2013;57(5):682–8. </plain></SENT>
<SENT sid="283" pm="."><plain>Epub 2013/07/13. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/cit337">10.1093/cid/cit337</ext-link> .<?supplied-pmid 23845950?>23845950 </plain></SENT>
</text></ref><ref id="pone.0183453.ref002"><text><SENT sid="284" pm="."><plain>2PharesCR, LynfieldR, FarleyMM, Mohle-BoetaniJ, HarrisonLH, PetitS, et al Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA. 2008;299(17):2056–65. </plain></SENT>
<SENT sid="285" pm="."><plain>Epub 2008/05/08. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.299.17.2056">10.1001/jama.299.17.2056</ext-link> .<?supplied-pmid 18460666?>18460666 </plain></SENT>
</text></ref><ref id="pone.0183453.ref003"><text><SENT sid="286" pm="."><plain>3OkikeIO, JohnsonAP, HendersonKL, BlackburnRM, Muller-PebodyB, LadhaniSN, et al Incidence, etiology, and outcome of bacterial meningitis in infants aged &lt;90 days in the United kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis. 2014;59(10):e150–7. </plain></SENT>
<SENT sid="287" pm="."><plain>Epub 2014/07/06. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciu514">10.1093/cid/ciu514</ext-link> .<?supplied-pmid 24997051?>24997051 </plain></SENT>
</text></ref><ref id="pone.0183453.ref004"><text><SENT sid="288" pm="."><plain>4SchuchatA. Group B streptococcus. Lancet. 1999;353(9146):51–6. </plain></SENT>
<SENT sid="289" pm="."><plain>Epub 1999/02/19. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(98)07128-1">10.1016/S0140-6736(98)07128-1</ext-link> .<?supplied-pmid 10023965?>10023965 </plain></SENT>
</text></ref><ref id="pone.0183453.ref005"><text><SENT sid="290" pm="."><plain>5SchragS, GorwitzR, Fultz-ButtsK, SchuchatA. Prevention of perinatal group B streptococcal disease. </plain></SENT>
<SENT sid="291" pm="."><plain>Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11):1–22. </plain></SENT>
<SENT sid="292" pm="."><plain>Epub 2002/09/05. .<?supplied-pmid 12211284?>12211284 </plain></SENT>
</text></ref><ref id="pone.0183453.ref006"><text><SENT sid="293" pm="."><plain>6DaheshS, HenslerME, Van SorgeNM, GertzREJr., SchragS, NizetV, et al Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52(8):2915–8. </plain></SENT>
<SENT sid="294" pm="."><plain>Epub 2008/06/11. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00461-08">10.1128/AAC.00461-08</ext-link> ;<?supplied-pmid 18541727?>18541727 </plain></SENT>
</text></ref><ref id="pone.0183453.ref007"><text><SENT sid="295" pm="."><plain>7KimuraK, SuzukiS, WachinoJ, KurokawaH, YamaneK, ShibataN, et al First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother. 2008;52(8):2890–7. </plain></SENT>
<SENT sid="296" pm="."><plain>Epub 2008/05/21. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00185-08">10.1128/AAC.00185-08</ext-link> ;<?supplied-pmid 18490507?>18490507 </plain></SENT>
</text></ref><ref id="pone.0183453.ref008"><text><SENT sid="297" pm="."><plain>8MurayamaSY, SekiC, SakataH, SunaoshiK, NakayamaE, IwataS, et al Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother. 2009;53(6):2650–3. </plain></SENT>
<SENT sid="298" pm="."><plain>Epub 2009/04/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01716-08">10.1128/AAC.01716-08</ext-link> ;<?supplied-pmid 19332682?>19332682 </plain></SENT>
</text></ref><ref id="pone.0183453.ref009"><text><SENT sid="299" pm="."><plain>9GaudreauC, LecoursR, IsmailJ, GagnonS, JetteL, RogerM. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother. 2010;65(3):594–5. </plain></SENT>
<SENT sid="300" pm="."><plain>Epub 2009/12/22. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jac/dkp458">10.1093/jac/dkp458</ext-link> .<?supplied-pmid 20022939?>20022939 </plain></SENT>
</text></ref><ref id="pone.0183453.ref010"><text><SENT sid="301" pm="."><plain>10NaganoN, NaganoY, KimuraK, TamaiK, YanagisawaH, ArakawaY. Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother. 2008;52(12):4258–67. </plain></SENT>
<SENT sid="302" pm="."><plain>Epub 2008/09/24. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00596-08">10.1128/AAC.00596-08</ext-link> ;<?supplied-pmid 18809936?>18809936 </plain></SENT>
</text></ref><ref id="pone.0183453.ref011"><text><SENT sid="303" pm="."><plain>11KimuraK, NaganoN, NaganoY, SuzukiS, WachinoJ, ShibayamaK, et al High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother. 2013;68(3):539–42. </plain></SENT>
<SENT sid="304" pm="."><plain>Epub 2012/11/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jac/dks423">10.1093/jac/dks423</ext-link> .<?supplied-pmid 23111853?>23111853 </plain></SENT>
</text></ref><ref id="pone.0183453.ref012"><text><SENT sid="305" pm="."><plain>12SekiT, KimuraK, ReidME, MiyazakiA, BannoH, JinW, et al High isolation rate of MDR group B streptococci with reduced penicillin susceptibility in Japan. J Antimicrob Chemother. 2015;70(10):2725–8. </plain></SENT>
<SENT sid="306" pm="."><plain>Epub 2015/07/15. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jac/dkv203">10.1093/jac/dkv203</ext-link> .<?supplied-pmid 26169560?>26169560 </plain></SENT>
</text></ref><ref id="pone.0183453.ref013"><text><SENT sid="307" pm="."><plain>13NaganoN, NaganoY, ToyamaM, KimuraK, TamuraT, ShibayamaK, et al Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1. J Antimicrob Chemother. 2012;67(4):849–56. </plain></SENT>
<SENT sid="308" pm="."><plain>Epub 2012/01/03. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jac/dkr546">10.1093/jac/dkr546</ext-link> .<?supplied-pmid 22210756?>22210756 </plain></SENT>
</text></ref><ref id="pone.0183453.ref014"><text><SENT sid="309" pm="."><plain>14BannoH, KimuraK, TanakaY, KitanakaH, JinW, WachinoJ, et al Characterization of multidrug-resistant group B streptococci with reduced penicillin susceptibility forming small non-Beta-hemolytic colonies on sheep blood agar plates. J Clin Microbiol. 2014;52(6):2169–71. </plain></SENT>
<SENT sid="310" pm="."><plain>Epub 2014/03/14. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.00226-14">10.1128/JCM.00226-14</ext-link> ;<?supplied-pmid 24622103?>24622103 </plain></SENT>
</text></ref><ref id="pone.0183453.ref015"><text><SENT sid="311" pm="."><plain>15ProctorRA, von EiffC, KahlBC, BeckerK, McNamaraP, HerrmannM, et al Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol. 2006;4(4):295–305. </plain></SENT>
<SENT sid="312" pm="."><plain>Epub 2006/03/17. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrmicro1384">10.1038/nrmicro1384</ext-link> .<?supplied-pmid 16541137?>16541137 </plain></SENT>
</text></ref><ref id="pone.0183453.ref016"><text><SENT sid="313" pm="."><plain>16ZbindenA, QuiblierC, HernandezD, HerzogK, BodlerP, SennMM, et al Characterization of Streptococcus tigurinus small-colony variants causing prosthetic joint infection by comparative whole-genome analyses. J Clin Microbiol. 2014;52(2):467–74. </plain></SENT>
<SENT sid="314" pm="."><plain>Epub 2014/01/31. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.02801-13">10.1128/JCM.02801-13</ext-link> ;<?supplied-pmid 24478475?>24478475 </plain></SENT>
</text></ref><ref id="pone.0183453.ref017"><text><SENT sid="315" pm="."><plain>17WellinghausenN, ChatterjeeI, BergerA, NiederfuehrA, ProctorRA, KahlBC. Characterization of clinical Enterococcus faecalis small-colony variants. J Clin Microbiol. 2009;47(9):2802–11. </plain></SENT>
<SENT sid="316" pm="."><plain>Epub 2009/07/17. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.00485-09">10.1128/JCM.00485-09</ext-link> ;<?supplied-pmid 19605585?>19605585 </plain></SENT>
</text></ref><ref id="pone.0183453.ref018"><text><SENT sid="317" pm="."><plain>18GrobnerS, BeckJ, SchallerM, AutenriethIB, SchulteB. Characterization of an Enterococcus faecium small-colony variant isolated from blood culture. Int J Med Microbiol. 2012;302(1):40–4. </plain></SENT>
<SENT sid="318" pm="."><plain>Epub 2011/10/05. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijmm.2011.07.001">10.1016/j.ijmm.2011.07.001</ext-link> .<?supplied-pmid 21968291?>21968291 </plain></SENT>
</text></ref><ref id="pone.0183453.ref019"><text><SENT sid="319" pm="."><plain>19AllegrucciM, SauerK. Formation of Streptococcus pneumoniae non-phase-variable colony variants is due to increased mutation frequency present under biofilm growth conditions. J Bacteriol. 2008;190(19):6330–9. </plain></SENT>
<SENT sid="320" pm="."><plain>Epub 2008/07/29. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JB.00707-08">10.1128/JB.00707-08</ext-link> ;<?supplied-pmid 18658260?>18658260 </plain></SENT>
</text></ref><ref id="pone.0183453.ref020"><text><SENT sid="321" pm="."><plain>20AllegrucciM, SauerK. Characterization of colony morphology variants isolated from Streptococcus pneumoniae biofilms. J Bacteriol. 2007;189(5):2030–8. </plain></SENT>
<SENT sid="322" pm="."><plain>Epub 2006/12/26. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JB.01369-06">10.1128/JB.01369-06</ext-link> ;<?supplied-pmid 17189375?>17189375 </plain></SENT>
</text></ref><ref id="pone.0183453.ref021"><text><SENT sid="323" pm="."><plain>21DeanMA, OlsenRJ, LongSW, RosatoAE, MusserJM. Identification of point mutations in clinical Staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione. Infect Immun. 2014;82(4):1600–5. </plain></SENT>
<SENT sid="324" pm="."><plain>Epub 2014/01/24. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.01487-13">10.1128/IAI.01487-13</ext-link> ;<?supplied-pmid 24452687?>24452687 </plain></SENT>
</text></ref><ref id="pone.0183453.ref022"><text><SENT sid="325" pm="."><plain>22BesierS, LudwigA, OhlsenK, BradeV, WichelhausTA. Molecular analysis of the thymidine-auxotrophic small colony variant phenotype of Staphylococcus aureus. Int J Med Microbiol. 2007;297(4):217–25. </plain></SENT>
<SENT sid="326" pm="."><plain>Epub 2007/04/07. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijmm.2007.02.003">10.1016/j.ijmm.2007.02.003</ext-link> .<?supplied-pmid 17412637?>17412637 </plain></SENT>
</text></ref><ref id="pone.0183453.ref023"><text><SENT sid="327" pm="."><plain>23KahlBC, BeckerK, LofflerB. Clinical significance and pathogenesis of staphylococcal small colony variants in persistent infections. Clin Microbiol Rev. 2016;29(2):401–27. </plain></SENT>
<SENT sid="328" pm="."><plain>Epub 2016/03/11. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CMR.00069-15">10.1128/CMR.00069-15</ext-link> ;<?supplied-pmid 26960941?>26960941 </plain></SENT>
</text></ref><ref id="pone.0183453.ref024"><text><SENT sid="329" pm="."><plain>24KubotaN, KuzumotoK, HidakaE, YoshizawaK, YumotoK, OanaK, et al First isolation of oleate-dependent Enterococcus faecalis small-colony variants from the umbilical exudate of a paediatric patient with omphalitis. J Med Microbiol. 2013;62(Pt 12):1883–90. </plain></SENT>
<SENT sid="330" pm="."><plain>Epub 2013/09/28. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/jmm.0.062752-0">10.1099/jmm.0.062752-0</ext-link> .<?supplied-pmid 24072765?>24072765 </plain></SENT>
</text></ref><ref id="pone.0183453.ref025"><text><SENT sid="331" pm="."><plain>25SendiP, FreiR, MaurerTB, TrampuzA, ZimmerliW, GraberP. Escherichia coli variants in periprosthetic joint infection: diagnostic challenges with sessile bacteria and sonication. J Clin Microbiol. 2010;48(5):1720–5. </plain></SENT>
<SENT sid="332" pm="."><plain>Epub 2010/03/26. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.01562-09">10.1128/JCM.01562-09</ext-link> ;<?supplied-pmid 20335421?>20335421 </plain></SENT>
</text></ref><ref id="pone.0183453.ref026"><text><SENT sid="333" pm="."><plain>26PincusSH, ColeRL, WesselsMR, CorwinMD, Kamanga-SolloE, HayesSF, et al Group B streptococcal opacity variants. J Bacteriol. 1992;174(11):3739–49. </plain></SENT>
<SENT sid="334" pm="."><plain>Epub 1992/06/11. ;<?supplied-pmid 1592825?>1592825 </plain></SENT>
</text></ref><ref id="pone.0183453.ref027"><text><SENT sid="335" pm="."><plain>27HansonBR, RunftDL, StreeterC, KumarA, CarionTW, NeelyMN. Functional analysis of the CpsA protein of Streptococcus agalactiae. J Bacteriol. 2012;194(7):1668–78. </plain></SENT>
<SENT sid="336" pm="."><plain>Epub 2012/01/31. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JB.06373-11">10.1128/JB.06373-11</ext-link> ;<?supplied-pmid 22287515?>22287515 </plain></SENT>
</text></ref><ref id="pone.0183453.ref028"><text><SENT sid="337" pm="."><plain>28KlinzingDC, MadoffLC, PuopoloKM. Genomic analysis identifies a transcription-factor binding motif regulating expression of the alpha C protein in Group B Streptococcus. Microb Pathog. 2009;46(6):315–20. </plain></SENT>
<SENT sid="338" pm="."><plain>Epub 2009/03/31. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.micpath.2009.03.003">10.1016/j.micpath.2009.03.003</ext-link> ;<?supplied-pmid 19328843?>19328843 </plain></SENT>
</text></ref><ref id="pone.0183453.ref029"><text><SENT sid="339" pm="."><plain>29KlinzingDC, IshmaelN, Dunning HotoppJC, TettelinH, ShieldsKR, MadoffLC, et al The two-component response regulator LiaR regulates cell wall stress responses, pili expression and virulence in group B Streptococcus. Microbiology. 2013;159(Pt 7):1521–34. </plain></SENT>
<SENT sid="340" pm="."><plain>Epub 2013/05/25. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/mic.0.064444-0">10.1099/mic.0.064444-0</ext-link> ;<?supplied-pmid 23704792?>23704792 </plain></SENT>
</text></ref><ref id="pone.0183453.ref030"><text><SENT sid="341" pm="."><plain>30MiyamotoM, MotookaD, GotohK, ImaiT, YoshitakeK, GotoN, et al Performance comparison of second- and third-generation sequencers using a bacterial genome with two chromosomes. BMC Genomics. 2014;15:699 Epub 2014/08/22. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2164-15-699">10.1186/1471-2164-15-699</ext-link> ;<?supplied-pmid 25142801?>25142801 </plain></SENT>
</text></ref><ref id="pone.0183453.ref031"><text><SENT sid="342" pm="."><plain>31WatanabeK, UenoM, KamiyaD, NishiyamaA, MatsumuraM, WatayaT, et al A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25(6):681–6. </plain></SENT>
<SENT sid="343" pm="."><plain>Epub 2007/05/29. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt1310">10.1038/nbt1310</ext-link> .<?supplied-pmid 17529971?>17529971 </plain></SENT>
</text></ref><ref id="pone.0183453.ref032"><text><SENT sid="344" pm="."><plain>32GottschalkB, BrokerG, KuhnM, AymannsS, Gleich-TheurerU, SpellerbergB. Transport of multidrug resistance substrates by the Streptococcus agalactiae hemolysin transporter. J Bacteriol. 2006;188(16):5984–92. </plain></SENT>
<SENT sid="345" pm="."><plain>Epub 2006/08/04. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JB.00768-05">10.1128/JB.00768-05</ext-link> ;<?supplied-pmid 16885467?>16885467 </plain></SENT>
</text></ref><ref id="pone.0183453.ref033"><text><SENT sid="346" pm="."><plain>33ForquinMP, TaziA, Rosa-FraileM, PoyartC, Trieu-CuotP, DramsiS. The putative glycosyltransferase-encoding gene cylJ and the group B Streptococcus (GBS)-specific gene cylK modulate hemolysin production and virulence of GBS. Infect Immun. 2007;75(4):2063–6. </plain></SENT>
<SENT sid="347" pm="."><plain>Epub 2007/02/07. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.01565-06">10.1128/IAI.01565-06</ext-link> ;<?supplied-pmid 17283108?>17283108 </plain></SENT>
</text></ref><ref id="pone.0183453.ref034"><text><SENT sid="348" pm="."><plain>34BakerLJ, DorockeJA, HarrisRA, TimmDE. The crystal structure of yeast thiamin pyrophosphokinase. Structure. 2001;9(6):539–46. </plain></SENT>
<SENT sid="349" pm="."><plain>Epub 2001/07/04. .<?supplied-pmid 11435118?>11435118 </plain></SENT>
</text></ref><ref id="pone.0183453.ref035"><text><SENT sid="350" pm="."><plain>35SchweingruberAM, DlugonskiJ, EdenharterE, SchweingruberME. Thiamine in Schizosaccharomyces pombe: dephosphorylation, intracellular pool, biosynthesis and transport. Curr Genet. 1991;19(4):249–54. </plain></SENT>
<SENT sid="351" pm="."><plain>Epub 1991/04/01. .<?supplied-pmid 1868574?>1868574 </plain></SENT>
</text></ref><ref id="pone.0183453.ref036"><text><SENT sid="352" pm="."><plain>36FankhauserH, ZurlindenA, SchweingruberAM, EdenharterE, SchweingruberME. Schizosaccharomyces pombe thiamine pyrophosphokinase is encoded by gene tnr3 and is a regulator of thiamine metabolism, phosphate metabolism, mating, and growth. J Biol Chem. 1995;270(47):28457–62. </plain></SENT>
<SENT sid="353" pm="."><plain>Epub 1995/11/24. .<?supplied-pmid 7499352?>7499352 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
